ANCA-associated Primary Necrotizing Vasculitides Clinical Trial
— STATVASOfficial title:
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
| Verified date | October 2022 |
| Source | Assistance Publique - Hôpitaux de Paris |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to assess whether rosuvastatin could reduce the subclinical markers of atherosclerosis and the incidence of major cardiovascular events in patients with primary necrotizing vasculitides.
| Status | Completed |
| Enrollment | 121 |
| Est. completion date | November 7, 2019 |
| Est. primary completion date | November 7, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: Patient > 18 years. ANCA-associated vasculitis: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss syndrome). Patients will fulfill the Chapel Hill Consensus Criteria and the American College of Rheumatology criteria, in remission of vasculitis. Patients in remission of vasculitis after induction therapy (for first flare or relapse), including corticosteroids associated or not with immunosuppressive agents according to Good Clinical Practice for the treatment of vasculitis, between 6 months and 10 years after the beginning of induction therapy. Patients with informed and signed consent Exclusion Criteria: Other systemic vasculitis. Secondary vasculitis (paraneoplastic or infectious). Patient with active vasculitis after induction therapy, requiring salvage therapy. Inability to sign informed consent. Inability to take the experimental treatment. Hypersensitivity to rosuvastatin or to any of the excipients. Pregnancy. Chronic HCV, HBV and/or HIV infection. Patient receiving other statin or other hypolipemic agent. Patient requiring treatment with statin according to Afssaps recommandations published in 2005 as primary or secondary prevention. Subclinical atherosclerosis that confers a high cardiovascular risk before patient randomization : - Carotid stenosis greater than 50% in diameter - Ectasia of the abdominal aorta - Intima-media thickening greater than 1.2 mm - Diffuse atherosclerosis lesions - Heterogeneous or hypoechoic prominent plaques greater than 2 mm Participation in another interventional study within 3 months before inclusion. Sick patients will not be excluded if they participate simultaneously in a strictlu observational study or a study with only blood samplings. Any medical or psycatric disease that could prevent from administrating drugs or from following-up the patient according to the protocol, and/or that would expose the patient to an important number of side effects, according to the principal investigator. Non affiliation to a social security system or any social protection system. |
| Country | Name | City | State |
|---|---|---|---|
| France | Hopital Cochin | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Assistance Publique - Hôpitaux de Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Mean change from baseline in mean carotid intima-media thickness for 2 predefined sites (distal common carotid arteries) | Assessed with B-mode ultrasound | 24 months | |
| Secondary | Annualized rate of change in mean carotid intima-media thickness for 2 predefined sites (distal common carotid arteries) | Assessed with B-mode ultrasound | 24 months | |
| Secondary | Mean change from baseline in the number of plaques in three peripheral vessels (carotid and femoral arteries and abdominal aorta) at 6, 12 and 24 months | Assessed with B-mode ultrasound | 24 months | |
| Secondary | Mean change from baseline in serum biomarkers of subclinical atherosclerosis at 6, 12 and 24 months | ultra-sensitive CRP, VCAM-1, P-selectin, thrombomodulin | 24 months | |
| Secondary | Rate of major cardiovascular events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes) | 24 months | ||
| Secondary | Rate of vasculitis relapses defined by BVAS>0 | 24 months | ||
| Secondary | Rate of adverse events | 24 months | ||
| Secondary | Mean change from baseline in lipid profile (triglycerids, total, HDL and LDL cholesterol) at 6, 12 and 24 months compared to baseline value. | 24 months |